Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trialAthol U. Wells, Daniel F. Dilling, Anand Devaraj et al.|The Lancet Respiratory Medicine|2020Cited by 558
Human Neutrophil Peptides and Phagocytic Deficiency in Bronchiectatic LungsStefanos Voglis, Haibo Zhang, Kieran L. Quinn et al.|American Journal of Respiratory and Critical Care Medicine|2009Cited by 57